중증 태변 흡인 증후군에서 폐표면 활성제 치료
Surfactant Therapy in Severe Meconium Aspiration Syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Meconium is a strong inactivator of pulmonary surfactant. The deficiency of surfactant or surfactant dysfunction may contribute to respiratory failure in a wide group of disorders, including meconium aspiration syndrome (MAS). We reviewed the effect of pulmonary surfactant therapy for severe MAS in ours as well as other countries. In general, surfactant therapy improves pulmonary oxygenation (oxygenation index or arterial/alveolar oxygen tension) and reduces the requirement for ventilation, and oxygen supplementation or hospitalization time. However,its effects on mortality and pulmonary or extrapulmonary complications are variable. In Korean studies, outborn infants are five times more common than inborn infants; therefore, the initial hospital care at delivery including adequate tracheal suctioning is important to improve the outcome of patients with severe MAS. To confirm the effect of surfactant therapy in MAS, additional well-designed,multicenter, randomized, controlled trials are needed. In addition, determining the optimal type of surfactant therapy (bolus, lavage, or combined) and the appropriate dose and duration of therapy is important.
Abstract
Meconium is a strong inactivator of pulmonary surfactant. The deficiency of surfactant or surfactant dysfunction may contribute to respiratory failure in a wide group of disorders, including meconium aspiration syndrome (MAS). We reviewed the effect of pulmonary surfactant therapy for severe MAS in ours as well as other countries. In general, surfactant therapy improves pulmonary oxygenation (oxygenation index or arterial/alveolar oxygen tension) and reduces the requirement for ventilation, and oxygen supplementation or hospitalization time. However,its effects on mortality and pulmonary or extrapulmonary complications are variable. In Korean studies, outborn infants are five times more common than inborn infants; therefore, the initial hospital care at delivery including adequate tracheal suctioning is important to improve the outcome of patients with severe MAS. To confirm the effect of surfactant therapy in MAS, additional well-designed,multicenter, randomized, controlled trials are needed. In addition, determining the optimal type of surfactant therapy (bolus, lavage, or combined) and the appropriate dose and duration of therapy is important.
참고문헌 (39)
- Avery ME, "Surface properties in relation to atelectasis and hyaline membrane disease", AMA J Dis Child, 97, pp.517~523 (1959)
- Fujiwara T, "Artificial surfactant therapy in hyaline-membrane disease", Lancet, 1, pp.55~59 (1980)
- Auten RL, "Surfactant treatment of full-term newborns with respiratory failure", Pediatrics, 87, pp.101~107 (1991)
- Blanke JG, "Surfactant therapy in severe neonatal respiratory failure-multicenter study-II. Surfactant therapy in 10 newborn infants with meconium aspiration syndrome", Klin Padiatr, 205, pp.75~78 (1993)
- Lewis JF, "The role of exogenous surfactant in the treatment of acute lung injury", Annu Rev Physiol, 65, pp.613~642 (2003)
- Raju TN, "Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis", J Pediatr, 123, pp.603~610 (1993)
- Herting E, "Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group", Pediatrics, 106, pp.957~964 (2000)
- Tibby SM, "Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis", Am J Respir Crit Care Med, 162, pp.1251~1256 (2000)
- Kurashima K, "A pilot study of surfactant inhalation in the treatment of asthmatic attack", Arerugi, 40, pp.160~163 (1991)
- Griese M, "Nebulization of a bovine surfactant in cystic fibrosis: a pilot study", Eur Respir J, 10, pp.1989~1994 (1997)
- Bos AP, "Surfactant replacement therapy in high-risk congenital diaphragmatic hernia", Lancet, 338, pp.1279~ (1991)
- Choi WJ, "The effect of pulmonary surfactant lavage and replacement theraTablepy in meconium aspiration pneumonia neonates", The 53th Annual Fall Meeting of the Korean Pediatric Society, 40 (2003), The Korean Pediatric Society
- Chen CT, "Effect of intra-alveolar meconium on pulmonary surface tension properties", Crit Care Med, 13, pp.233~236 (1985)
- Moses D, "Inhibition of pulmonary surfactant function by meconium", Am J Obstet Gynecol, 164, pp.477~481 (1991)
- Bae CW, "Morphology and function of pulmonary surfactant inhibited by meconium", Pediatr Res, 44, pp.187~191 (1998)
- Cleary GM, "Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration", Pediatrics, 100, pp.998~1003 (1997)
- Sun B, "Surfactant inhibition in experimental meconium aspiration syndrome", Acta Paediatr, 82, pp.182~189 (1993)
- Dargaville PA, "Surfactant and surfactant inhibitors in meconium aspiration syndrome", J Pediatr, 138, pp.113~115 (2001)
- Vidyasagar D, "Inflammatory response and apoptosis in newborn lungs after meconium aspiration", Biotechnol Prog, 21, pp.192~197 (2005)
- Okazaki K, "Serum cytokine and chemokine profiles in neonates with meconium aspiration syndrome", Pediatrics, 121, pp.e748~e753 (2008)
- de Beaufort AJ, "Meconium is a source of pro-inflammatory substances and can induce cytokine production in cultured A549 epithelial cells", Pediatr Res, 54, pp.491~495 (2003)
- De Luca D, "Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration", Intensive Care Med, 35, pp.321~326 (2009)
- Kääpä P, "Phospholipase A2 in meconium-induced lung injury", J Perinatol, 28(Suppl 3), pp.S120~S122 (2008)
- Khammash H, "Surfactant therapy in full-term neonates with severe respiratory failure", Pediatrics, 92, pp.135~139 (1993)
- Findlay RD, "Surfactant replacement therapy for meconium aspiration syndrome", Pediatrics, 97, pp.48~52 (1996)
- Lam BC, "Surfactant lavage for meconium aspiration syndrome: a pilot study", Pediatrics, 103, pp.1014~1018 (1999)
- Wiswell TE, "A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome", Pediatrics, 109, pp.1081~1087 (2002)
- Chinese Collaborative Study Group for Neonatal Respiratory Diseases, "Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial", Acta Paediatr, 94, pp.896~902 (2005)
- Dargaville PA, "Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome", J Pediatr, 158, pp.383~389 (2011)
- "Phase III randomized study of lucinactant in full term newborn infants with meconium aspiration syndrome" (2012)[URL]
- Luo FF, "Effect of pulmonary surfactant therapy in neonates with meconium aspiration syndrome: a meta-analysis", Zhongguo Dang Dai Er Ke Za Zhi, 14, pp.413~417 (2012)
- Cho YJ, "A case of massive pulmonary hemorrhage treated with pulmonary surfactant replacement", J Korean Soc Neonatol, 6, pp.258~262 (1999)
- 손수민, "준 만삭 이상아에서 폐표면 활성제 보충요법의 성적", Korean Journal of Pediatrics, 50(12), pp.1200~1205 (2007), 대한소아과학회
- 최보연, "A case of acute respiratory distress syndrome treated with surfactant and low dose methylprednisolone", Korean Journal of Pediatrics, 49(4), pp.455~459 (2006), 대한소아과학회
- 박종훈, "산모혈액 흡인에 의한 급성 호흡곤란 증후군 1례", 대한주산의학회잡지, 20(1), pp.74~77 (2009), 대한주산의학회
- 박상우, "중증 양수 흡인성 폐렴의 임상양상 및 폐표면 활성제 보충요법의 효과", Korean Journal of Pediatrics, 52(4), pp.429~434 (2009), 대한소아과학회
- 최창원, "중증 태변흡입증후군의 임상적 특성", Korean Journal of Pediatrics, 51(7), pp.713~721 (2008), 대한소아과학회
- 이순민, "중증 태변 흡인 증후군에서 인공 폐표면활성제 세정요법의 효과에 관한 비교 연구", Korean Journal of Pediatrics, 51(4), pp.367~371 (2008), 대한소아과학회
- 최혜정, "폐 출혈을 동반한 호흡 부전 신생아의 외인성 계면 활성제의 치료", 대한주산의학회잡지, 22(4), pp.319~328 (2011), 대한주산의학회